Frequently asked questions about AURLUMYN
No. AURLUMYN has no contraindications and no known drug interactions. Additionally, AURLUMYN has not been shown to initiate systemic bleeding.1 Review the safety and tolerability profile.
Initiate the infusion at a rate of 0.5 ng/kg/min; increase in increments of 0.5 ng/kg/min every 30 minutes, up to 2 ng/kg/min.1
Administer as continuous infusion for 6 hours each day up to a maximum of 8 consecutive days.1
While AURLUMYN should be administered as soon as possible after rewarming, wilderness medicine experts recommend AURLUMYN as a first-line therapy for the treatment of severe frostbite up to 48 and possibly up to 72 hours after rewarming.3,* Review the AURLUMYN dosing regimen and learn more about the treatment-initiation window.
*Per wilderness medicine guidelines, the treatment-initiation window post-rewarming is 24 hours with thrombolytic therapy and up to 72 hours with iloprost IV. In a case study of 5 climbers with severe frostbite, 4 of whom received iloprost IV treatment between 48 and 72 hours from injury/rewarming, 2 had results with minimal tissue loss and 2 had results with tissue loss less than expected.3,4
In the open-label, randomized, controlled trial of iloprost IV, the risk of amputation was predicted by the presence of an anomaly on a bone scintigraphy performed 7 days after initial clinical presentation of frostbite in at least one finger/toe affected by severe frostbite.1 See the results from the study.
AURLUMYN is available through multiple distributors. See ordering information.
Download our replacement policy and request form and instructions for ordering replacements here.
Puts digit preservation within reach
AURLUMYN is the only FDA-approved treatment for severe frostbite in adults to reduce the risk of digit amputations.1
FDA=US Food and Drug Administration.
INDICATIONS AND USAGE
AURLUMYN is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in young, healthy adults who suffered frostbite at high altitudes.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
AURLUMYN may cause symptomatic hypotension. Correct hypotension prior to administration of AURLUMYN. Monitor vital signs while administering AURLUMYN.
Adverse Reactions
Adverse events reported with the use of intravenous (IV) iloprost in patients with frostbite include headache, flushing, palpitations/tachycardia, nausea, vomiting, dizziness, and hypotension.
Use in Specific Populations
- Advise women not to breastfeed during treatment with AURLUMYN.
- The safety and efficacy of AURLUMYN in pediatric patients have not been established.
- Dosage adjustment is recommended in patients with moderate or severe hepatic impairment.
- In patients with eGFR <30 mL/min, dosage adjustment can be considered based on tolerability. The effect of dialysis on the clearance of AURLUMYN has not been evaluated.
To report suspected adverse reactions, contact BTG at 1-877-377-3784 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
- AURLUMYN (iloprost) [prescribing information]. BTG International, Inc.
- Cauchy E, Cheguillaume B, Chetaille E. A controlled trial of a prostacyclin and rt-PA in the treatment of severe frostbite. N Engl J Med. 2011;364(2):189-190; Cheguillaume B. Controlled trial of iloprost and iloprost and rt-PA in the treatment of severe frostbite. Doctoral thesis. Grenoble School of Medicine; 2011.
- McIntosh SE, Freer L, Grissom CK, et al. Wilderness Medical Society Clinical Practice Guidelines for the Prevention and Treatment of Frostbite: 2024 Update. Wilderness Environ Med. 2024;35(2):183-197.
- Pandey P, Vadlamudi R, Pradhan R, Pandey KR, Kumar A, Hackett P. Case report: severe frostbite in extreme altitude climbers—the Kathmandu iloprost experience. Wilderness Environ Med. 2018;29(3):366-374.
